News
May 27, 2025
Asep Medical Validates its SepsetER Diagnostic Test in Patients in Leading Scientific Journal, Nature Communications.
May 8, 2025
Asep Medical Announces Cease Trade Order
April 12, 2025
Asep Medical Announces Proposed Share Consolidation
April 1, 2025
Asep Medical Announces $1,343,699 Debt Settlement
February 15, 2025
Asep Medical Announces $440,585 Debt Settlement
April 8, 2024
Asep Joint Venture Company, SepSMART, obtains Business License and is Formally Registered in China
March 14, 2024
Asep Medical Confirms the Use of AI Enables Improved Treatments for Common Biofilm Infections and Rapid Sepsis Diagnostics.
February 28, 2024
Asep Medical’s Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis
December 29, 2023
ASEP INC. ANNOUNCES CLOSING OF DEBT SETTLEMENT
December 23, 2023
ASEP INC. ANNOUNCES CLOSING OF THE FIRST TRANCHE OF LIFE OFFERING
November 30, 2023
ASEP ANNOUNCES PRIVATE PLACEMENT OF UP TO $2 MILLION
November 27, 2023
Asep Medical Holdings Inc. is Granted Patent Approval for its AI-based Sepsis Diagnostic Technology in the US
November 22, 2023
Asep Medical Holdings Inc. Signs Joint Venture Agreement with Leading Chinese Medical Diagnostics Company Sansure Biotech Inc.
November 20, 2023
Asep Inc. in Final Stage of Approval Process for NASDAQ Listing Registration Statement
July 18, 2023
Another Breakthrough — Asep Inc.’s A.I.-Based Sepsis Technology Identifies COVID-19 Severity from a Blood Sample
June 20, 2023
Asep Inc. Founder, Chair and CEO, Dr. Robert E. W. Hancock, Ranked 4th Best Microbiologist in the World
June 19, 2023
Asep Inc. Undertakes Final Steps Toward NASDAQ Listing
January 20, 2023
Asep Medical Holdings Inc. Announces Adoption of Long-term Performance Incentive Plan, Grant of Stock Options
January 18, 2023
Asep Medical Holdings Inc. to Hold Important Investor Information Webinar on January 24, 2023
December 28, 2022
CLARIFICATION Asep Medical Holdings Inc. Provides Update on its Prior Disclosure Regarding Proprietary Diagnostic & Therapeutic Technologies
December 24, 2022
Asep Medical Holdings Inc. Achieves Significant Milestones Addressing Antibiotic Failure Through Proprietary Diagnostic & Therapeutic Technologies
December 22, 2022
Asep Inc. Completes Non-Brokered Private Placement of a $330,000 Unsecured Convertible Debenture
December 2, 2022
Asep Medical Holdings Inc. Enters into Commercial Agreement to Acquire SafeCoat Medical Inc.
November 24, 2022
Asep Medical Holdings Inc. Announces Grant of Stock Options
November 23, 2022
Asep Medical Holdings Inc. Announces Listing of its Common Shares on the Frankfurt Stock Exchange
November 7, 2022
Asep Inc. is Granted Patent Approval for its Sepsis Diagnostic Technology in 13 European Countries and Australia
October 4, 2022
Dr. Richard Heinzl, Physician, Humanitarian, Entrepreneur and Author Appointed to Asep Inc.’s Board of Directors
July 19, 2022
Asep Medical Inc. Announces Appointment of Dr. Robert E. W. Hancock as CEO and Chairman
June 7, 2022
Asep Medical Holdings Inc. Receives Revocation of Cease Trade Order from the BC Securities Commission.
April 26, 2022
Asep Medical Holdings Inc. Announces Additional Listing to the OTCQB Venture Market in the U.S.
March 22, 2022
Asep Medical Holdings Inc. Announces Compelling Results of an Independent Sepsis Study Prepared by RTI Health Solutions
March 3, 2022
Asep Medical Holdings Inc. to Hold Online Investor Information Webinar on March 3, 2022
February 19, 2022
Asep Medical Inc. Announces its Antibiofilm/Anti-inflammatory Peptide Technology is in Advanced Development for Wound Dressings with US Army Funding1
ASEP and its subsidiaries' technologies have not received marketing authorization
and are not currently available for purchase. © 2023 All Rights Reserved